PRESS RELEASES

Date Title and Summary View
May 9, 2019
Summary ToggleZafgen Reports First Quarter 2019 Operating and Financial Results
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061              Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated in Q2 2019 PATH for PWS study continues enrollment with strong support
Summary ToggleZafgen Reports First Quarter 2019 Operating and Financial Results
May 2, 2019
Summary ToggleZafgen to Announce First Quarter 2019 Financial Results
BOSTON , May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will announce
Summary ToggleZafgen to Announce First Quarter 2019 Financial Results
Apr 4, 2019
Summary ToggleZafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that on
Summary ToggleZafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 13, 2019
Summary ToggleZafgen to Present at the 31st Annual ROTH Conference
BOSTON , March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield
Summary ToggleZafgen to Present at the 31st Annual ROTH Conference
Mar 11, 2019
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies Expanded executive team with highly
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
Mar 7, 2019
Summary ToggleZafgen to Present at the Cowen and Company 39th Annual Health Care Conference
BOSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield
Summary ToggleZafgen to Present at the Cowen and Company 39th Annual Health Care Conference
Mar 6, 2019
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
BOSTON , March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
Mar 4, 2019
Summary ToggleZafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development
BOSTON , March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced the appointment of
Summary ToggleZafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development
Jan 17, 2019
Summary ToggleZafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061
Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose relative to placebo Progressive and notable body weight loss occurred at the 1.8 mg dose Results continue
Summary ToggleZafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061
Nov 26, 2018
Summary ToggleZafgen Provides Update on Investigational New Drug Application for ZGN-1061
BOSTON , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that the Company
Summary ToggleZafgen Provides Update on Investigational New Drug Application for ZGN-1061